Wedbush Raise Lexicon Pharmaceuticals (LXRX) PT to $33 as Primary Endpoint Reached

September 9, 2016 11:57 AM EDT
Get Alerts LXRX Hot Sheet
Price: $16.19 --0%

Rating Summary:
    5 Buy, 3 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 8
Trade LXRX Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Wedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $33.00 after sotagliflozin achieves its primary endpoint in first T1D phase III trial.

Moussatos commented, "With inTandem1 for Type 1 diabetes (T1D) largely a success on the efficacy and safety front, we look for similar results from the Ph2 JDRF and inTandem2 studies in Q4. We believe positive results from these trials could put LXRX on track for filing for regulatory approval of sotagliflozin in T1D alone if the FDA agrees to accept a T1D NDA for review in H1:17."

For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.

Shares of Lexicon Pharmaceuticals closed at $15.31 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Liana Moussatos

Add Your Comment